



18th Vaccine Congress

8-11 September 2024 • Altis Grand Hotel, Lisbon, Portugal



Sunday, 8th September 2024

17:00 - 18:30

Registration and Welcome Drinks Reception

Londres

Monday, 9th September 2024

09:00 - 10:40

Opening Plenary Session

Europa

Chair: Gregory A. Poland

Presentation type: Oral

09:00-09:20 Opening Remarks by Conference Chair Gregory A. Poland

09:20 - 10:00 [KN01] Rachael Schneerson - John Robbins Award Lecture

Exploiting the flexibility of mRNA therapeutics for vaccination

Galit Alter

Moderna, USA

10:00 - 10:40 [KN02] Edward Jenner Vaccine Award Lecture

Vaccines as tools for health equity (Virtual Presentation)

Kathleen Neuzil

Fogarty International Center, NIH, USA

10:40 - 11:10

Refreshment Break

Londres

11:10 - 11:45

Early Career Researcher Award

Europa

Chair: Gregory A. Poland

Presentation type: Oral

11:10 - 11:45 [KN03] Early Career Award Lecture

Immunologic approaches to emerging and re-emerging RNA viruses

David Martinez

Yale University School of Medicine, New Haven, CT, USA

11:45 - 13:00

Breakout Session 1 - Computational Design of New Vaccines (AI) (AI approaches in Vaccine Development)

Europa

Chairs: Albert C. Shaw, Angela Rasmussen

Presentation type: Oral

11:45 - 12:15 [INV01]

Discovering new relationships between antibody responses and CMV transmission with deep learning

Margaret E. Ackerman

Thayer School of Engineering and Geisel School of Medicine, USA

12:15 - 12:30 [O1.1]

AI-Supported SEIHCRD Modeling of Smallpox Outbreaks: Evaluating Vaccination Strategies and Herd Immunity Impact in the French Population

Tristan Learoyd, Kevin Yeo, Laura Cochrane

Emergent BioSolutions Inc, Gaithersburg, MD, UK

12:30 - 12:45 [O1.2]

Curated datasets and appropriate metrics: An adequate approach to validating T-cell epitope prediction models, resulting in better experimental results

Grzegorz Preibisch^{1,2}, Stanislaw Giziński², Michał Tyrolski², Michał Rembalski², Piotr Kucharski², Anna Gambin¹

¹University of Warsaw, Warszawa, Poland. ²Deepflare.ai, Poland

12:45 - 13:00 [O1.3]

Development of a broadly protective AI-Immunology™ identified Neisseria gonorrhoeae mRNA vaccine

Sophie Schussek¹, Frances Lees², Sunita Gulati³, Gerhardt Boukes², Caryn Fenner², Pär Comstedt¹, Sanjay Ram³, Amin Khan², Andreas Mattsson¹

Breakout Session 2 - Vaccines against STI's

Roma

Chairs: Carlos Del Rio, Lee H. Harrison

Presentation type: Oral

11:45 - 12:15 [INV02]

An Effective Vaccine for Gonorrhea: Are We There Yet?

Valeria D. Cantos

Emory University School of Medicine, Atlanta, GA, USA

12:15 - 12:45 [INV03]

Dissecting human antibody responses to mpox

Raianna Fantin¹, Bailey Bozarth¹, Alesandro Civljak¹, Igor Lobo¹, Hallie Cohn¹, Valter Monteiro², Seokchan Park¹, Michael Schotsaert¹, Goran Bajic¹, Carolina Lucas², Camila Coelho¹

¹Icahn School of Medicine at Mount Sinai, New York, NY, USA. ²Yale University School of Medicine, New Haven, CT, USA

12:45 - 13:00 [O2.1]

Long-term protection of 4CMenB against gonorrhoea to 4 years after implementation of an adolescent 4CMenB vaccine program in South Australia

Helen Marshall^{1,2,3}, Bing Wang^{1,2,4}, Lynne Giles^{1,4,5}, Prabha Andraweera^{1,2,4}, Mark McMillan^{1,2,4}, Sara Almond⁶, Rebecca Beazley⁶, Janine Mitchell⁶, Jana Sisnowski⁶, Charlotte Bell⁶, Louise Flood⁶, James Ward⁷

¹The University of Adelaide Faculty of Health and Medical Sciences, Adelaide, Australia. ²Women's and Children's Health Network, North Adelaide, Australia.

³The University of Adelaide, Robinson Research Institute, Sheffield, Australia.

⁴The University of Adelaide Robinson Research Institute, North Adelaide, Australia.

⁵The University of Adelaide School of Public Health, Adelaide, Australia.

⁶SA Health, Adelaide, Australia. ⁷The University of Queensland Poche Centre for Indigenous Health, Saint Lucia, Australia

13:00 -
14:00

Lunch

Rio de Janeiro

14:00 -
15:30

Breakout Session 3 - Controlled Human Infection Models in Vaccine Development and Evaluation

Europa

Chairs: David Weber, Daniela Weiskopf

Presentation type: Oral

14:00 - 14:30 [INV04]

Evaluating The Role of Controlled Human Infection Models in Vaccine Development

Christine Dahlke

Coalition for Epidemic Preparedness Innovations, Oslo, Norway

14:30 - 14:45 [O3.1]

Controlled human infection models in vaccine development

Mohamed Al-Ibrahim, Hunter Sheils

Pharmaron CPC, USA

14:45 - 15:00 [O3.2]

The immunomodulatory potential of different lipid nanoparticles and mRNAs derived from authorized vaccines

Katharina Walther¹, Josephine Friedrich², Katrin Bagola¹, Max Bastian², Ger van Zandbergen¹

¹Paul-Ehrlich-Institute, Langen, Germany. ²Friedrich-Loeffler-Institute Federal Research Institute for Animal Health, Greifswald, Germany

15:00 - 15:15 [O3.3]

Discovery and evaluation of promising novel vaccine candidates for Lyme borreliosis and other tick-borne diseases based on tick salivary proteins

Alexis Burnham¹, Abhijeet Nayak¹, Šíma Radek², Ondřej Hajdušek², Veronika Pavlasová², Juan Anguita³, Tim Schuijt¹, Joppe Hovius¹

¹Amsterdam University Medical Center, Center for Experimental and Molecular Medicine, The Netherlands. ²Biology Centre Czech Academy of Sciences, České Budějovice, Czech Republic. ³Center for Cooperative Research in Biosciences, Derio, Spain

15:15 - 15:30 [O3.4]

Evolution of the Bacillus Calmette-Guérin scar Russia and Moreau strains in newborns: A Brazilian cohort

Ramon De Souza¹, Susan Pereira¹, Florisneide Barreto¹, Carlos Santos^{2,3}, Carla Lima⁴, Isabella Castelo⁵, Marcio Natividade⁵, Jacy Andrade⁶, Mauricio Barreto⁷

¹Institute of Public Health of the Federal University of Bahia, Brazil. ²Centre for Data and Knowledge Integration for Health (CIDACS), Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Bahia, Brazil, Brazil. ³State University of Feira de Santana, FEIRA DE SANTANA, Brazil. ⁴Federal University of Bahia School of Nursing, SALVADOR, Brazil. ⁵Federal University of Bahia, SALVADOR, Brazil. ⁶Federal University of Bahia, Faculty of Medicine, Department of Pediatrics, SALVADOR, Brazil. ⁷Centre for Data and Knowledge Integration for Health (CIDACS), Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Bahia,, Brazil

15:30 -
16:00

Refreshment Break

Londres

16:00 -
17:30

Breakout Session 5 - Vaccines against mosquito and tick borne diseases

Europa

Chairs: Tony Fooks, Angela Rasmussen

Presentation type: Oral

16:00 - 16:30 [INV07]

Development of vaccines against mosquito- and tick-borne diseases transmitted by viruses

Alan Barrett

University of Texas Medical Branch, Galveston, TX, USA

16:30 - 16:45 [O5.1]

Down-selection of a Next-generation Malaria Vaccine using the Epitope Disk Nanoparticle, a Disease Agnostic Vaccine Platform

Emma Ryan¹, Shelby Foor¹, Dallas Brown¹, William Harrison¹, Paul Robben¹, Tyree Wilson¹, Robin Miller², Lorraine Soisson², Adrian Batchelor¹, Sheetij Dutta¹

¹Walter Reed Army Institute of Research, Silver Spring, MD, USA. ²USAID, Washington, DC, USA

Breakout Session 4 - Immunisation of Special Risk Groups

Roma

Chairs: Nigel Crawford, Amy Chung

Presentation type: Oral

14:00 - 14:30 [INV05]

Vaccination in cellular therapy patients

Benjamin Teh

Peter MacCallum Cancer Centre Infectious Diseases and Infection Prevention Research, Melbourne, Australia

14:30 - 15:00 [INV06]

Illustrations of distinct vaccine-induced immune responses in vulnerable pediatric populations

Paolo Palma

Bambino Gesù Children's Research Hospital IRCCS, Roma, Italy. University of Rome Tor Vergata Department of Medicine of the Systems, Roma, Italy

15:00 - 15:15 [O4.1]

Impact of COVID-19 mRNA vaccination on Metabolic Profiles in Patients with Hematological Malignancies

Joann Diray-Arce

Boston Children's Hospital, Boston, MA, USA. Harvard Medical School, Boston, MA, USA

15:15 - 15:30 [O4.2]

Predictors of human papillomavirus vaccination behaviour in human immunodeficiency virus-positive South African women

Josephina Senyatsi¹, Zeenat Ismail^{1,2}, Johanna Meyer^{1,2}, Rosemary Burnett^{1,2}

¹Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.

²South African Vaccination and Immunisation Centre, Sefako Makgatho Health Sciences University, Pretoria, South Africa

Breakout Session 6 - Socio Political Implications of Vaccination and Vaccine Policy

Roma

Chairs: Carlos Del Rio, Helena Maltezos

Presentation type: Oral

16:00 - 16:30 [INV08]

Struggles around policy: law, vaccines, and politics

Dorit Reiss

UC law San Francisco (formerly UC Hastings), San Francisco, CA, USA

16:30 - 16:45 [O6.1]

Assessing the Real-World Impact of the Yellow Fever Vaccine: A Comprehensive Analysis

Madison Farnsworth, Kamil Khanipov, Kostiantyn Botnar, Scott Weaver, George Golovko

The University of Texas Medical Branch at Galveston, Galveston, TX, USA

16:45 - 17:00 [O6.2]

16:45 - 17:00 [O5.2]

Preclinical model development for the assessment of vaccines against Rift Valley Fever virus

Emma Kennedy, Kimi Ebisine, Stephen Findlay-Wilson, Lucy Flett, Emma Rayner, Roger Hewson, Stuart Dowall
UK Health Security Agency (UKHSA), UK

17:00 - 17:15 [O5.3]

Evidence to recommendation for chikungunya vaccine introduction: stakeholder perspectives

Hyolim Kang¹, Kaja Abbas^{1,2}

¹London School of Hygiene & Tropical Medicine, London, UK. ²Nagasaki University, Nagasaki, Japan

17:15 - 17:30 [O5.4]

Advances in Plasmodium vivax malaria vaccine: immunogenicity and efficacy of a Circumsporozoite Protein-based formulation adjuvanted with nanoemulsion in mice

Irene Soares¹, Rodolfo Marques¹, Ana Luiza Maia², Ana Clara Gazzinelli², Flavia Bagno², Renata Salgado², Isabela Gomes², Natalia Castro², Diana Gomes², Graziella Rivelli², Xiomara Gaitán¹, Daniel Bargieri¹, Rogerio Amino³, Ana Paula Fernandes², Santuza Teixeira², Ricardo Gazzinelli²

¹University of São Paulo, Brazil. ²Federal University of Minas Gerais, BELO HORIZONTE, Brazil. ³Institut Pasteur, Paris, France

Provider recommendations, school encouragement, and COVID-19 vaccination of hesitant parents' children

Don Willis¹, James Selig¹, C'asia James², Morgan Gurel-Headley¹, Stacy Zimmerman², Eduardo Ochoa², Shashank Kraleti², Ji Li¹, Pearl McElfish¹

¹University of Arkansas for Medical Sciences - Northwest Regional Campus, Fayetteville, AR, USA. ²University of Arkansas for Medical Sciences, Little Rock, AR, USA

17:00 - 17:15 [O6.3]

Post introduction evaluation of COVID-19 vaccine deployment in Ghana: lessons learnt to inform future new vaccine introductions and strengthen public health readiness, 2023

Naziru Tanko Mohammed¹, Kwame Amponsa-Achiano¹, Angela Shen², Eunice Baiden Laryea³, Emmanuel Sally¹, Michael Adjei⁴, William Opare⁵, Fred Osei-Sarpong⁴, John Bawa⁶, George Bonsu⁶, Danielle Barradas³, Julie Carlton⁷, Franklin Asiedu-Bekoe⁸, Patrick Kuma-Aboagye⁹

¹Expanded Programme on Immunization, Ghana Health Service, Ghana.

²TaskForce for Global Health, USA. ³US Centers for Disease Control and Prevention, Ghana. ⁴World Health Organization, Ghana. ⁵Expanded Programme on Immunization, Ghana. ⁶PATH, Ghana. ⁷US Centers for Disease Control and Prevention, USA. ⁸Public Health Division, Ghana Health Service, Ghana. ⁹Ghana Health Service, Ghana

17:15 - 17:30 [O6.4]

Impact of the COVID-19 Epidemic on HPV Vaccination Recommendation Notification by Japanese Local Governments

Toshiyuki Sugai¹, Masuko Saito², Hiromitsu Ogata³, Sonoko Azuma⁴, Etsuko Miyagi⁵

¹Prefectural University of Hiroshima Faculty of Health and Welfare, Hiroshima, Japan. ²Kansai University of International Studies School of Health Science Department of Nursing, Miki, Japan. ³Kagawa Nutrition University, Sakado, Japan. ⁴Japanese Red Cross College of Nursing, Shibuya-Ku, Japan. ⁵Yokohama City University Graduate School of Medicine Department Obstetrics and Gynecology, Yokohama, Japan

17:30 - 19:00

Drinks Reception, Poster Session 1 & Meet the Editors of journal Vaccine and Vaccine X

Londres
Presentation type: Poster

Tuesday, 10th September 2024

08:00 - 09:00

NIH Peer Review Session

Europa

Chairs: Albert C. Shaw, Jian Wang

The National Institutes of Health (NIH) administers >\$45B (FY22) of federal funding for extramural medical research, supports over 300,000 scientists and 2,500 institutions across the United States. These funds are competitively awarded through a two-stage review process. The first level of review solely evaluates the scientific merit of an application by convening peer reviewers who are experts in the field to adjudicate the potential impact of the proposed research. The second level of review takes into consideration for funding both the scientific impact of a proposal as well as its responsiveness to NIH programmatic objectives. The NIH Center for Scientific Research (CSR) oversees the majority of first-level reviews with the mission of ensuring that these are expertly and fairly evaluated in accordance with the NIH policies of rigor, transparency, and review integrity.

CSR upholds its mission of maintaining high standards in peer review by implementing standardized processes across all review panels. Each study section is headed by a scientific review officer (SRO), who serves as the designated federal official during the review meeting. The SRO mostly recruits experts from outside the federal government to assess the scientific merit of the applications, oversees reviewer training, and implements CSR policies and best practices. Proposals that score in the top ~50% for preliminary overall impact scores are discussed. All proposals receive the written critiques of the three assigned reviewers. For applications discussed at the meeting, the SRO additionally provides a resume of discussion. The summary statement is the primary outcome of the first level of review and is used by program staff at funding institutes during the second level of review to make funding recommendations.

If you would like to learn more about the CSR peer review process as an applicant or have interest in serving as a reviewer, please visit: www.csr.nih.gov [<http://www.csr.nih.gov>]

09:00 - 11:00

Plenary Session 2 - Vaccines against Influenza (Avian and Human Influenza)

Europa

Chairs: Florian Krammer, Arthur Reingold

Presentation type: Oral

09:00 - 09:20 [KN04]

Development of mRNA-1083, a multi-component Influenza/COVID-19 vaccine candidate

Benoit Callendret

Moderna, The Netherlands

09:20 - 09:40 [KN05]

An overview of pan-zoonotic highly pathogenic H5N1 avian influenza virus

Florian Krammer

Icahn School of Medicine at Mount Sinai, USA. Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Austria

09:40 - 10:00 [KN06]

One health approaches to controlling avian influenza including highly pathogenic H5N1

Alyson Kelvin

10:00 - 10:15 [OP2.1]

Repeated influenza vaccination effects in a randomized placebo-controlled trial (the DRIVE study)

Ben Cowling¹, Jefferson Santos², Sooksan Wong¹, Natalie Kwok³, Lisa Touyon¹, Jordan Ort², Naiqing Ye², Samuel Cheng¹, Patrick Wilson³, John Tsang⁴, Richard Webby⁵, Sophie Valkenburg⁶, Malik Peiris¹, Nancy Leung¹, Scott Hensley², Sarah Cobey⁷

¹The University of Hong Kong School of Public Health, Hong Kong, Hong Kong. ²University of Pennsylvania Department of Microbiology, Philadelphia, PA, USA.

³Weill Cornell Medicine, New York, NY, USA. ⁴Yale University School of Medicine, New Haven, CT, USA. ⁵St. Jude Children's Research Hospital, Memphis, TN, USA.

⁶The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. ⁷University of Chicago Department of Ecology and Evolution, Chicago, IL, USA

10:15 - 10:30 [OP2.2]

Cellular responses to past H2N2 influenza virus: a matter of antigen exposure or age?

Afshin Zariri, Koen van de Ven, Stefanie Lenz, Harry van Dijken, Natascha Wolf, Lisa Wijsman, Jørgen de Jonge
National Institute for Public Health and the Environment, Bilthoven, The Netherlands

10:30 - 11:00

Panel Discussion

11:00 -
11:30

Refreshment Break

Londres

11:30 -
13:00

Breakout Session 7 - Vaccine Durability/Memory/Adjuvants

Europa

Chairs: Ken Ishii, Inna Ovsyannikova

Presentation type: Oral

11:30 - 12:00 [INV09]

Adjuvants – The Tool to Obtain the Required Immune Responses in Vaccination

Dennis Christensen

Croda Pharma, Frederikssund, Denmark

12:00 - 12:15 [O7.1]

Oral norovirus bivalent vaccine elicits durable systemic and mucosal responses in a phase 2 trial of young and elderly adults

Becca A. Flitter, Susan Greco, Nick D'Amato, Maria Apkarian, Lam Nguyen, Nick Lamb, Elena Neuhaus, Molly R. Braun, Sean N. Tucker, James F. Cummings
Vaxart Inc, South San Francisco, CA, USA

12:15 - 12:30 [O7.2]

Sustained protection of 4CMenB against invasive meningococcal disease 5 years after implementation of an infant and adolescent program

Helen Marshall^{1,2,3}, Bing Wang^{1,2,3}, Lynne Giles^{1,3}, Prabha Andraweera^{4,3,1}, Mark McMillan^{1,3,2}, Rebecca Beazley⁵, Noel Lally⁶, Jana Sisnowski⁶, Louise Flood⁶

¹The University of Adelaide Faculty of Health and Medical Sciences, Adelaide, Australia. ²Women's and Children's Health Network, North Adelaide, Australia.

³The University of Adelaide Robinson Research Institute, North Adelaide, Australia. ⁴Women's and Children's Hospital Adelaide, North Adelaide, Australia. ⁵SA Health, Australia. ⁶SA Health, Adelaide, Australia

12:30 - 12:45 [O7.3]

A Novel Genetic Vaccine Platform Using Tag/Catcher Conjugation for Modular Assembly and Secretion of Antigen-Displaying Capsid Virus-Like Particles

Cyrielle Fougereux¹, Louise Goksøyr¹, sven Hagen¹, Mireia Rocavert², Anna Okholm³, Wian De Jongh¹, Adam Sander¹

¹AdaptVac, Denmark. ²University of Copenhagen, København, Denmark.

³University of Copenhagen, København, Denmark

12:45 - 13:00 [O7.4]

Serum anti-Shigella LPS IgG and bactericidal activity levels induced by Shigella conjugate vaccines and natural infection

Valeria Asato¹, Shiri Meron-Sudai¹, Anya Bialik¹, Yuval Fikler¹, Calman A. MacLennan^{2,3}, Dani Cohen¹

¹Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. ²Bill & Melinda Gates Foundation, UK. ³Jenner Institute, Nuffield Department of Medicine, University of Oxford, UK

Breakout Session 8 - Maternal Immunization

Roma

Chairs: Lee H. Harrison, Flor Munoz-Rivas

Presentation type: Oral

11:30 - 12:00 [INV10]

Progress towards a Group B streptococcal vaccine

Paul Heath

St George's University of London, London, UK

12:00 - 12:15

Moderated panel discussion

12:15 - 12:30 [O8.1]

Seroprevalence of Bordetella pertussis antibodies in Libyan pregnant women at the time of delivery

Suleiman Abusrewil^{1,2}, Mostafa Gowas³, Ali Amgadmi³, Inas Alhudiri⁴, Marwan Sherif⁵, Fawzi Ebrahim⁴, Salah Tabal⁴, Yosra Lamami⁴, Musa Busarira⁶, Adam Elzagheid⁴

¹Tripoli University Hospital, Tripoli, Libya. ²University of Tripoli, Tripoli, Libya.

³Tripoli University Hospital, Libya. ⁴Libyan Biotechnology Research Center, Libya. ⁵Libyan Board of medical Specialities, Libya. ⁶University of Benghazi, Benghazi, Libya

12:30 - 12:45 [O8.2]

The exclusion of pregnant women from an Ebola vaccine trial in Boende, western DRC: Perceptions of (excluded) women and community members

Maha Salloum¹, Antea Paviotti¹, Ynke Larivière¹, Freddy Bikioli Bolombo^{2,1}, Trésor Zola Matuvanga^{2,1}, Gwen Lemey¹, Vivi Maketa², Hypolite Muhindo Mavoko², Pierre Van Damme¹, Patrick Mitashi Mulopo², Hilde Bastiaens¹, Jean-Pierre Van Geertruyden¹

¹University of Antwerp, Antwerpen, Belgium. ²University of Kinshasa, Kinshasa, Democratic Republic of Congo

12:45 - 13:00 [O8.3]

Covid19 vaccination among 1.5 million pregnant women in France in 2021 and 2022: description of uptake and frequencies of preterm birth, maternal death and neonatal death, using the nationwide national health system (SNDS)

Sylvie Escolano, Elise Quentin, Hong Duong, Ismail Ahmed, Pascale Tubert-Bitter

Université Paris-Saclay, UVSQ, Inserm, CESP, High-Dimensional Biostatistics for Drug Safety and Genomics, Villejuif, France, Villejuif, France

13:00 -
13:15

Lunch

Rio de Janeiro

13:15 -
13:45

Researcher Academy - Author Workshop

Roma

Chair: Dior Beerens

13:45 -
14:00

14:00 -
15:30

Breakout Session 9 - Vaccine Hesitancy

Europa

Chairs: Gregory A. Poland, Ken Ishii

Presentation type: Oral

14:00 - 14:30 [INV11]

Trust and vaccine acceptance during COVID-19: Evidence from Denmark and beyond

Michael Bang Petersen

Aarhus University, Aarhus, Denmark

14:30 - 14:45 [O9.1]

Shifting the dial: Vaccine safety intelligence for informing community conversations

Hazel Clothier^{1,2}, Aishwarya Shetty¹, Hannah Morgan^{1,2}, Muhammad Javed¹, Sedigh Khademi Habibabadi¹, Gerardo Luis Dimaguila¹, Jim Buttery^{1,2}

¹Epi-Informatics, Centre for Health Analytics, Melbourne Children's Campus, Australia. ²The University of Melbourne Department of Paediatrics, Parkville, Australia

14:45 - 15:00 [O9.2]

Malaria Vaccine Introduction in Cameroon, Population Acceptance, and Associated Factors in 2024: A Nationwide Cross-Sectional Study

Andreas Ateke Njoh^{1,2}, Eugene Justine Kongnyuy², Tchokfe Shalom Ndoula¹,

Adidja Amani³, Jerome Nyhalah Dinga⁴, Ibrahima Madaina⁵, Muluh Ngwe

Sonnet Ticha¹, Messang Blandine Abizou⁶, Laurent Cleenewerck de Kiev²

¹Expanded Program on Immunization, Ministry of Public Health, Cameroon.

²EUCLID, Bangui, Central African Republic. ³World Health Organization

Regional Office for Africa, Brazzaville, Congo. ⁴University of Buea, Buea,

Cameroon. ⁵Expanded Program on Immunization, Ministry of Public Health,,

Cameroon. ⁶Faculty of Medicine and Biomedical Sciences, University of

Yaounde 1, Cameroon

15:00 - 15:15 [O9.3]

A systematic review of measures of healthcare workers' vaccine confidence

Kofoworola Akinsola¹, Ayobami Bakare^{1,2}, Elisa Gobbo², Carina King², Claudia

Hanson^{2,3,4}, Adegoke Falade¹, Sibylle Herzig van Wees²

¹University College Hospital, Nigeria. ²Karolinska Institute, Stockholm, Sweden.

³London School of Hygiene & Tropical Medicine, London, UK. ⁴The Aga Khan

University - Kenya, Nairobi, Kenya

15:15 - 15:30 [O9.4]

Strengthening capacity for tailored immunization programs using the adult learning principles: a case study from Nigeria.

Chisom Obi-Jeff^{1,2}, Funmilayo Oguntimehin¹, Abduljaleel Adejumo¹, Olympus

Ade-Banjo¹, Dan Gadzama³, Nicholas Okoli³, Abdulrahman Ibrahim¹, Chidera

Obi¹, Rachael Olorupo¹, Ifeyinwa Martins¹, Amina Usman³, Audu Joy³, Tanko

Chadwafwa³, Anthony Onimisi¹

¹Brooks Insights, Nigeria, Nigeria. ²London School of Hygiene & Tropical

Medicine, London, UK. ³Federal Capital Territory Primary Health Care Board,

Nigeria

Breakout Session 10 - Vaccines for Neglected Diseases

Roma

Chairs: Maria Elena Bottazzi, Daniela Weiskopf

Presentation type: Oral

14:00 - 14:30 [INV12]

Clinical Development of Vaccines Targeting High Burden Neglected Tropical Diseases

David Diemert¹, Maria Elena Bottazzi², Jeffrey Bethony¹, Peter Hotez²

¹The George Washington University, Washington, DC, USA. ²Baylor College of Medicine, Houston, TX, USA

14:30 - 14:45 [O10.1]

Schistosomiasis vaccine: Human clinical trials in USA and Africa

Afzal Siddiqui

Texas Tech University Health Sciences Center, Lubbock, TX, USA

14:45 - 15:00 [O10.2]

Advancement in Leishmania vaccination development and its role in global elimination of leishmaniasis

Hira Nakhasi

Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation Research, US Food and Drug Administration, USA

15:00 - 15:15 [O10.3]

The magnitude and mechanisms of protection against homologous and heterologous Salmonella challenge induced to outer-membrane vesicles with different O-antigen lengths

Areej Alshayea¹, Sian Jossi¹, Edith Marcial-Juarez¹, Marisol Pérez-Toledo¹, Ruby

Persaud¹, Anna Schager¹, Daniel Larsen², Gvantsa Gutishvili³, Jamie Pillay¹,

Fernanda Escobar-Riquelme¹, Jack Bryant⁴, William Horsnell⁵, Manuel

Banzhaf⁴, Jakub Kaczmarek⁶, Peter Højrup², James Gumbart³, Ian Henderson⁷,

Vassiliy Bavro⁸, Constantino López-Macías⁹, Adam Cunningham¹

¹University of Birmingham Institute of Immunology and Immunotherapy,

Birmingham, UK. ²University of Southern Denmark, Odense, Denmark. ³Georgia

Institute of Technology, Atlanta, GA, USA. ⁴University of Birmingham College of

Medical and Dental Sciences, Birmingham, UK. ⁵University of Cape Town

Institute of Infectious Disease and Molecular Medicine, Rondebosch, South

Africa. ⁶Ovodan Biotech A/S, Denmark. ⁷The University of Queensland Institute

for Molecular Bioscience, Saint Lucia, Australia. ⁸University of Essex School of

Life Sciences, Colchester, UK. ⁹Mexican Social Security Institute, Ciudad de

México, Mexico

15:15 - 15:30 [O10.4]

Challenges in Scrub Typhus Vaccine Development: Altered Humoral Immune Responses during Acute infection in Mouse Models

Lynn Soong

The University of Texas Medical Branch, USA

15:30 -
17:00

Refreshment Break and Poster Session 2

Londres

Presentation type: Poster

17:00 -
18:30

Breakout Session 11 - Roundtable on Syndromic Surveillance of Vaccine-Associated Adverse Events: The Need for a New Paradigm

Europa

Chairs: Gregory A. Poland

Presentation type: Oral

Introduction

Case Report and Description of recent Vaccine Commentary on Cryptic Adverse Events by Gregory A. Poland, Mayo Clinic, USA

Presentation of the Data Demonstrating Tinnitus as a Vaccine-Associated Adverse Event by Jim Buttery, Murdoch Children's Research Institute, Australia

Description of Syndromic Surveillance and Australia's System by Jim Buttery, Murdoch Children's Research Institute, Australia

Q&A

19:30 -
22:00

Conference Dinner (Ticketed)

Museu da Cerveja

Dinner Speaker: Gregory A. Poland

Editor in Chief, Vaccine and Vaccine X, Mayo Clinic, USA

Wednesday, 11th September 2024

08:00 -
09:00

Breakfast of Leaders in Vaccinology with New Investigators/Trainees

Roma

Chair: Carlos Del Rio

Learn about developing a career in vaccinology and clinical research

09:00 -
11:00

Plenary Session 3 - RSV: A review of existing vaccines and those in later stage development

Europa

Chairs: Nigel Crawford, Flor Munoz-Rivas

Presentation type: Oral

09:00 - 09:30 [KN07]

RSV Prevention in Pediatrics

Yvonne Maldonado

Stanford University School of Medicine, Stanford, CA, USA

09:30 - 10:00 [KN08]

RSV Prevention in Adults

Evan Anderson

Moderna, USA

10:00 - 10:30 [KN09]

U.S. experience with RSV immunization products from the 2023-2024 RSV season

Amadea Britton, Michael Melgar, Katherine Fleming-Dutra

Centers for Disease Control and Prevention, Atlanta, GA, USA

10:30 - 10:45 [OP3.1]

Respiratory syncytial virus – burden of disease on healthcare in a central hospital in Portugal

André Cartaxo¹, Sofia Rocha¹, Andreia Meseiro², Susana Peres¹, Cristina Toscano³, David Ranhel³, Gabriela Rodrigues³, Ana Cláudia Miranda¹, Kamal Mansinho¹

¹Hospital Centre of West Lisbon Campus Hospital of Egas Moniz, Lisboa, Portugal. ²Barreiro Montijo Hospital Centre, Barreiro, Portugal. ³Hospital Centre of West Lisbon, Lisboa, Portugal

10:45 - 11:00 [OP3.2]

Skin-based vaccination in pigs: veterinary vaccine development or research model?

Inés C6-Rives, Ann Ying-An Chen, Anne C. Moore

University College Cork Department of Biochemistry and Cell Biology, Cork, Ireland

11:00 -
11:30

Refreshment Break

Londres

11:30 -
13:00

Breakout Session 12 - Hot Topics

Europa

Chairs: Rick Kennedy, Arthur Reingold

Presentation type: Oral

11:30 - 12:00 [INV13]

ERINHA's contribution to vaccine development in Europe and beyond

Jonathan Ewbank

European Research Infrastructure on Highly Pathogenic Agents (ERINHA), Belgium

12:00 - 12:15 [O12.1]

A skin patch for improved thermostability and accessibility of mRNA vaccines for all

Deborah E. Pascoe¹, Xuan Bui¹, Alexandra C. I. Depelseñaire¹, Danushka K. Wijesundara¹, Christopher L. D. McMillan², David A. Muller², Angus Forster¹

¹Vaxxas Pty Ltd, Brisbane, Australia. ²The University of Queensland School of Chemistry and Molecular Biosciences, Brisbane, Australia

12:15 - 12:30 [O12.2]

The Global Vaccine Data Network™: a multinational collaboration generating real-world evidence for safer immunisation

Hazel Clothier^{1,2,3}, Yannan Jiang⁴, Jennifer Griffin⁴, Jeff Harrison¹, Helen Petousis-Harris^{1,5}, Steven Black¹, Jim Buttery^{1,2,3}

¹Global Vaccine Data Network, University of Auckland, Parkville, New Zealand.

²Epi-Informatics, Centre for Health Analytics, Melbourne Children's Campus, Australia.

³The University of Melbourne Department of Paediatrics, Parkville, Australia.

⁴Global Vaccine Data Network, University of Auckland, New Zealand.

⁵Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Science, University of Auckland, New Zealand

12:30 - 12:45 [O12.3]

Transcriptomics analyses to identify the signatures for differences in immune responses to vaccinations in the VITAL cohort

Manas Joshi¹, Christophe Carré², Alper Çevirgel³, Yannick van Sleen¹, Elske Bijvank³, Virginie Courtois², Emilie Chautard², Martine Chabaud-Riou², Daniel Larocque², Wivine Burny⁴, Lisa Beckers³, Anne-Marie Buisman³, Nynke Rots³, Marieke van der Heiden¹, Josine van Beek³, Debbie van Baarle^{1,3}

Breakout Session 13 - Veterinary Vaccines/One Health

Roma

Chairs: Maria Elena Bottazzi, Angela Rasmussen

Presentation type: Oral

11:30 - 12:00 [INV14]

One Health prevention, and a possible role for prepandemic vaccines

Marion Koopmans

Erasmus MC, The Netherlands

12:00 - 12:15 [O13.1]

The first USDA approved equine leptospirosis vaccine: A university, industry, and equine clinician collaborative One Health success story

Craig Carter^{1,2}, Margaret Steinman¹, Jacqueline Smith¹, Erdal Erol¹, Gloria Gellin¹, Stuart Brown³, Bruce Kaplan⁴, Rohini Roopnarine⁵, Jacquelin Boggs⁶, Noah Cohen⁷

¹University of Kentucky Department of Veterinary Science, Lexington, KY, USA.

²University of Kentucky College of Public Health, Lexington, KY, USA.

³Keeneland Association Inc, Lexington, KY, USA. ⁴One Health Initiative, USA. ⁵St George's University School of Veterinary Medicine, St George's, Grenada.

⁶Zoetis Genetics, Kalamazoo, MI, USA. ⁷Texas A&M University School of Veterinary Medicine & Biomedical Sciences, College Station, Texas, College Station, TX, USA

12:15 - 12:30 [O13.2]

A yeast-based vaccine elicits strong cell-mediated immunity in the bovine mammary gland

Célya Danzelle¹, Patricia Cunha¹, Florence B. Gilbert¹, Pierre Germon¹, Pascal Rainard¹, Rodrigo P. Martins²

¹INRAE, Université de Tours. UMR1282 Infectiology and Public Health, France.

²INRAE, Université de Tours. UMR1282 Infectiology and Public Health, Nouzilly, France

12:30 - 12:45 [O13.3]

A live, attenuated vaccine reduces the human foodborne pathogen Salmonella in commercial poultry

Shawn Bearson¹, Bradley Bearson², Melissa Monson¹, Samuel Whelan¹

¹USDA, ARS, National Animal Disease Center, Food Safety and Enteric Pathogens Research Unit, USA. ²USDA, ARS, National Laboratory for

¹University Medical Centre Groningen, Groningen, The Netherlands. ²Sanofi Pasteur Research and Development Centre Marcy-l'Etoile, Marcy l'Etoile, France. ³National Institute for Public Health and the Environment, Bilthoven, The Netherlands. ⁴GSK Vaccines, Wavre, Belgium

12:45 - 13:00 [O12.4]

Infodemiology Improves Vaccine Confidence through Health Systems Integration

Jessica Rivera¹, Joe Smyzer²

¹deBeaumont Foundation, USA. ²Public Good Projects, USA

Agriculture and the Environment, Agroecosystems Management Research Unit, USA

12:45 - 13:00 [O13.4]

Evaluation of three Infectious Bovine Rhinotracheitis (IBR) live marker vaccines in calves

Cecilia Righi¹, Alessandra Martucciello², Giovanna Cappelli², Claudia Torresi¹, Eleonora Scoccia¹, Carlo Grassi², Monica Giammarioli¹, Giulia Costantino¹, Esterina De Carlo², Cristina Casciari¹, Roberto Sabato¹, Francesco Feliziani¹, Stefano Petrini¹

¹National Reference Centre for Infectious Bovine Rhinotracheitis (IBR), Istituto Zooprofilattico Sperimentale Umbria-Marche, "Togo Rosati," Perugia, Italy.

²National Reference Centre for Hygiene and Technology of Breeding and Buffalo Production, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Salerno, Italy

13:00 -
13:45

Lunch

Rio de Janeiro

13:45 -
15:15

Spotlight on Pressing Vaccinology Issues - Dual Use Research of Concern

Europa

Chairs: Tony Fooks, Angela Rasmussen

Presentation type: Oral

13:45 - 14:00 Dual-use Awareness and Assessment in Research by Rik Bleijs, National Institute of Public Health and the Environment (RIVM), Netherlands

14:00 - 14:15 Toward a collaborative, collective and integrative international biological security education by Lijun Shang, London Metropolitan University, UK

14:15 - 14:30 Marion Koopmans, Erasmus MC, The Netherlands

14:30 - 14:45 Emerging issues in US biosecurity policy by Gigi Gronvall, John Hopkins University, USA

14:45 - 15:00 Jonathan Ewbank, ERINHA, Belgium

15:00 - 15:15 Panel Discussion

15:15 -
15:30

Closing Remarks

Europa

Chair: Gregory A. Poland

Presentation type: Oral